Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism (VTE)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on the MAGEC system for spinal lengthening in children with scoliosis (curvature of the spine)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating active relapsing–remitting multiple sclerosis (MS)
This guidance has been updated and replaced by NICE technology appraisal guidance 340.
Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..
This guidance has been updated and replaced by NICE technology appraisal guidance 402.
Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin
Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion
Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip
Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma
NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy
Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people
This guidance has been updated and replaced by NICE technology appraisal guidance 401.
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia
Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults
Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel
This guidance has been updated and replaced by NICE diagnostics guidance 34.
This guideance has been updated and replaced by NICE technology appraisal guidance 422.
This guidance has been updated and replaced by NICE technology appraisal guidance TA421.
Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration
In March 2019, NICE reviewed this guidance and recommended it should be withdrawn because Vision Amniotic Leak Detector is no longer available. NICE has produced a medtech innovation briefing on AmnioSense for unexplained vaginal wetness in pregnancy. For a copy of the review decision, please contact email@example.com.
The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.
Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder
This guidance has been updated and replaced by NICE technology appraisal guidance 386.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism
NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with
Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of
Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
This guidance has been updated and replaced by NICE technology appraisal guidance 504.
NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...
Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis